Clinical trial · Interventional
Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.
Study on Pharmacokinetics of Moxifloxacin in Serum and Liver Tissue of Patients Undergoing Liver Resection Due to Primary or Secondary Tumor of the Liver
NCT01302951CI-TRIAL-00004465MOXIcompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Side-effect of Antibiotic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Moxifloxacin 400 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Moxifloxacin
- description
- Moxifloxacin 400 mg i.v.
- interventionNames
- Drug: Moxifloxacin 400 mg
- type
- NO_INTERVENTION
- label
- No drug
- description
- 2 Patients were included as controls- no MXF given
Primary outcomes (1)
- measure
- Concentration (mg/L) of moxifloxacin in liver tissue
- timeFrame
- 1.5 hours after moxifloxacin infusion
- description
- The first outcome of this study was to analyze the concentration of MFX in liver tissue of patients who received MFX 400 mg i.v..
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * age 18-80 years old * elective liver resection of liver tumor * in females: pregnancy test negative * Subjects willing and able to give fully informed written consent Exclusion Criteria: * subjects with contra-indications to Moxifloxacin * subjects under therapy with Moxifloxacin within 2 weeks before recruitment
References
Publications (2)
- BACKGROUNDWeinrich M, Scheingraber S, Stremovskaia T, Schilling MK, Kees F, Pistorius GA. Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery. Int J Antimicrob Agents. 2006 Sep;28(3):221-5. doi: 10.1016/j.ijantimicag.2006.04.012. Epub 2006 Aug 14. PMID 16904875
- DERIVEDJustinger C, Schilling MK, Kees MG, Kauffels A, Hirschmann K, Kopp B, Kees F, Kollmar O. Penetration of moxifloxacin into liver tissue. Int J Antimicrob Agents. 2012 Jun;39(6):505-9. doi: 10.1016/j.ijantimicag.2012.01.022. Epub 2012 Apr 21. PMID 22526014